Researchers have developed an injectable hydrogel to co‐deliver macrophage‐targeting nanocarriers and CD47 antibodies into the postoperative tumor cavity of GBM, enabling in situ editing of local macrophages to generate CAR‐M capable of targeting and eliminating glioblastoma stem cells (GSCs) [119]. The gene discussed is CD47; the disease is neoplasm.